Alumis (ALMS) vs Helus Pharma (HELP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Helus Pharma (HELP) has outperformed Alumis (ALMS) over the past year, gaining 71.2% versus a gain of 57.3%. Alumis is the larger company by market cap ($926.8 million vs $862.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | HELP |
|---|---|---|
| Share price | $7.16 | $11.80 |
| Market cap | $926.76M | $862.11M |
| 1-day change | +2.73% | +10.07% |
| YTD return | -28.59% | +31.05% |
| 1-year return | +57.34% | +71.25% |
| 5-year return | — | -85.68% |
| EPS (TTM) | $-3.86 | $-4.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.35 | $15.15 |
| 52-week low | $4.28 | $3.76 |
| Distance from 52-week high | -77.16% | -22.11% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +348.74% | +237.54% |
| Average volume | 2.44M | 1.77M |
| Shares outstanding | 129.44M | 73.06M |
| Employees | 237 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HELP has outperformed ALMS by 13.9 percentage points over the past year.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 237 employees
About Helus Pharma
HELP stock →Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
ALMS vs HELP FAQ
Which is bigger, Alumis or Helus Pharma?
Alumis (ALMS) is larger, with a market capitalization of $926.76M compared with $862.11M for Helus Pharma (HELP).
Which stock has performed better over the past year, ALMS or HELP?
HELP returned +71.25% over the past 12 months, compared with +57.34% for ALMS (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and Helus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.